Actis's antisense angiogenesis inhibitor enters Phase III trials in India
This article was originally published in Scrip
Executive Summary
Actis Biologics' angiogenesis inhibitor, angiozyme, has entered Phase III clinical development in India for the treatment of colorectal cancer.